Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P24522

UPID:
GA45A_HUMAN

ALTERNATIVE NAMES:
DNA damage-inducible transcript 1 protein

ALTERNATIVE UPACC:
P24522; Q5TCA7; Q5TCA8

BACKGROUND:
The Growth arrest and DNA damage-inducible protein GADD45 alpha, known alternatively as DNA damage-inducible transcript 1 protein, is integral to the cellular defense mechanism against DNA damage. It serves as a regulator of p38 MAPKs in T-cells, preventing p88 phosphorylation, and plays a role in modulating PCNA interaction with CDK complexes. This activity is essential for promoting DNA excision repair and for inhibiting premature S phase entry, thereby maintaining genomic integrity.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Growth arrest and DNA damage-inducible protein GADD45 alpha offers a promising avenue for the development of novel therapeutic approaches. Its critical role in DNA repair and cell cycle control makes it a valuable target for interventions aimed at diseases involving DNA damage and cell cycle dysregulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.